Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Research & Development (2010 - 2026)

Lite Strategy (LITS) posted Research & Development of $30000.0 for Q1 2026, down 34.78% on a QoQ basis from $46000.0 in Q4 2025, and down 91.87% year-over-year from $369000.0 in Q1 2025.

Analysis

Lite Strategy (LITS) Research & Development (2010 - 2026) Analysis & Trends

Lite Strategy has reported Research & Development for 17 years, with the latest figure at $30000.0 in Q1 2026.

  • On a quarterly basis, Research & Development fell 91.87% year-over-year to $30000.0 in Q1 2026; TTM through Mar 2026 was $169000.0, a 97.83% decrease from a year earlier, with the FY2025 full-year figure at $3.9 million, down 76.31% from the prior year.
  • Research & Development was $30000.0 for Q1 2026 at Lite Strategy, down from $46000.0 in the prior quarter.
  • The five-year high for Research & Development was $22.3 million in Q1 2022, with the low at $10000.0 in Q3 2025.
  • Average Research & Development over 5 years is $6.9 million, with a median of $3.5 million recorded in 2023.
  • The sharpest annual moves came in 2024 and 2025: Research & Development jumped 53.46% in 2024, then slumped 99.68% in 2025.
  • Over 5 years, Research & Development stood at $15.3 million in 2022, then tumbled by 74.45% to $3.9 million in 2023, then tumbled by 92.13% to $308000.0 in 2024, then slumped by 85.06% to $46000.0 in 2025, then plunged by 34.78% to $30000.0 in 2026.
  • The last three Research & Development figures came in at $30000.0 (Q1 2026), $46000.0 (Q4 2025), and $10000.0 (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 1.87 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 1.76 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 993.80 Mn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 1.63 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -486.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 651.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 413.13 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 529.60 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 202.02 Mn
10 Lite Strategy 38.03 Mn 30.49 Mn - 30,000.00
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 30,000.00
Dec 31, 2025 46,000.00
Sep 30, 2025 10,000.00
Jun 30, 2025 83,000.00
Mar 31, 2025 369,000.00
Dec 31, 2024 308,000.00
Sep 30, 2024 3.16 Mn
Jun 30, 2024 3.94 Mn
Mar 31, 2024 5.22 Mn
Dec 31, 2023 3.91 Mn
Sep 30, 2023 3.49 Mn
Jun 30, 2023 2.57 Mn
Mar 31, 2023 15.10 Mn
Dec 31, 2022 15.31 Mn
Sep 30, 2022 19.46 Mn
Jun 30, 2022 21.84 Mn
Mar 31, 2022 22.32 Mn
Dec 31, 2021 21.53 Mn
Sep 30, 2021 19.95 Mn
Jun 30, 2021 16.29 Mn